Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Active not recruiting 2Recruiting 1

Sponsor Class

NETWORK 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Breast Neoplasms 5Prostatic Neoplasms 3Stage I Prostate Adenocarcinoma AJCC v7 1Sexual Dysfunctions, Psychological 1Prostate Adenocarcinoma 1PSA Level Greater Than Two 1Hormone Sensitive Prostate Cancer 1HER2 Negative Breast Cancer 1Castrate Sensitive Prostate Cancer 1Breast Neoplasms, Male 1Advanced Breast Cancer 1

Interventions

Magnetic Resonance Spectroscopy 28enzalutamide 23Specimen Handling 20apalutamide 17Androgen Antagonists 14Radiosurgery 13Radiotherapy 12Prednisone 12Docetaxel 12Abiraterone Acetate 12abiraterone 10Biopsy 10Radiation 8niraparib 6luprolide acetate gel depot 6darolutamide 6Pluvicto 6Leuprolide 62-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 6relugolix 5gallium 68 PSMA-11 5cabazitaxel 5acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 5Nivolumab 5Gonadotropin-Releasing Hormone 5bicalutamide 4Triptorelin Pamoate 4Surveys and Questionnaires 4Radiotherapy, Intensity-Modulated 4Glutamate Carboxypeptidase II 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Prostatic Neoplasms × Goserelin × 30 days × Clear all
NCT04423211 2026-05-15

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Eastern Cooperative Oncology Group

Phase 3 Recruiting
804 enrolled
Genitourinary

Prostatic Neoplasms

NCT04484818 2026-05-05

Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study

Eastern Cooperative Oncology Group

Phase 3 Active not recruiting
27 enrolled
Genitourinary

Prostatic Neoplasms

NCT04513717 2026-05-04

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

NRG Oncology

Phase 3 Active not recruiting
2,753 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡